Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Interferon-Alfa 9MU · 1 trial · 1 indication
PFS was defined as the interval from the date of randomization until the earlier date of progression or death. Progression was assessed by independent imaging reviewers using Response Evaluation Criteria in Solid Tumors (RECIST) criteria which is 20% increase in sum of longest diameter of target lesions from nadir (the lowest blood counts); measurable increase in non-target lesion; appearance of new lesions.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Bevacizumab 10 mg/kg intravenous (IV) q8wks + Temsirolimus 25 mg IV weekly |
| 2 | ACTIVE_COMPARATOR | Bevacizumab 10 mg/kg intravenous (IV) q8wks + Interferon-Alfa 9MU SC TIW |
| Name | Type | Description |
|---|---|---|
| Bevacizumab | DRUG | Bevacizumab 10 mg/kg intravenous (IV) q8wks |
| Temsirolimus | DRUG | Temsirolimus 25 mg IV weekly |
| Interferon-Alfa 9MU | DRUG | Interferon-Alfa 9MU SC TIW |
Inclusion Criteria: * Histologically and/or cytologically confirmed to have advanced renal cell carcinoma (RCC) * Majority component of conventional clear-cell type is mandatory * At least 1 measurable lesion (per RECIST) Exclusion Criteria: * Prior systemic treatment for RCC * Evidence of curren...
Interferon-Alfa 9MU is used for the treatment of renal cell carcinoma, a type of kidney cancer. It is being studied as part of a combination therapy regimen for patients with advanced disease. The drug is currently in Phase 3 clinical development.
Interferon-Alfa 9MU is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with renal cell carcinoma.
Interferon-Alfa 9MU is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the results will help determine whether the drug can be submitted for regulatory approval.
Interferon-Alfa 9MU is being evaluated in a Phase 3 clinical trial registered under the identifier NCT00631371. This completed study compared the combination of bevacizumab plus temsirolimus versus bevacizumab plus Interferon-Alfa in patients with advanced renal cell carcinoma. The trial enrolled 791 participants across multiple countries.
Interferon-Alfa 9MU is a small molecule drug. Its specific molecular target has not been disclosed in the available information, so its exact mechanism of action is not described here. The drug is being studied for its potential to treat renal cell carcinoma.